



Report on the Progress of Pandemic Influenza (H1N1) Vaccination in Latin America and the Caribbean (LAC) 23 April 2010

1) Advances in Vaccination Campaigns

It is estimated that LAC countries and territories will have access to approximately 170 million doses of Pandemic Influenza (H1N1) vaccine to cover the risk groups estimated by Ministries of Health of the Member States. Countries and territories in the Region have acquired the vaccine through 4 sources: direct purchase of the vaccine through the PAHO Revolving Fund (23 countries); vaccine donation from WHO (10 countries), vaccine donation from Spain (7 countries); direct purchase (2 countries); and mixed purchase from suppliers (1 country).

Graphic 1. Procurement of Vaccine against Pandemic Influenza (H1N1) in LAC.

	Number of countries and territories	Number of doses allocated	Number of doses received*
Revolving Fund (RF) PAHO	23	20.5 million	20.2 million
WHO Donation	7	6.6 million	1.7 million
WHO Donation and RF purchase	3	2.5 million	1 million
Direct purchase	2	40 million	40 million
Mixed purchase	1	100 million	100 million
Total	33	170 million	162.9 million


*Information updated as of 23 April 2010

Twenty three countries in the Region have initiated the vaccination of risk groups including: Anguilla, Argentina, Bahamas, Barbados, Belize, Bermuda, Brazil, Cayman Islands, Colombia, Costa Rica, Ecuador, El Salvador, Guatemala, Honduras, Mexico, Montserrat, Nicaragua, Panama, Peru, Suriname, Trinidad and Tobago, and Uruguay; with approximately 59 million doses administered as of 23 April. Approximately, 400



million doses have been applied globally. Country vaccination coverage is presented in the next graphic.

Graphic 2. Vaccination Coverage by Country in LAC.



*No official vaccination coverage data available. †Initiated vaccination two weeks ago.

2) Vaccine acquisition

2.1) PAHO Revolving Fund (RF):

- 23 countries have purchased 20,251,020 doses of vaccine through the RF, 16,916,810 without adjuvant (Sanofi-Pasteur and Novartis) and 3,334,210 with adjuvant (Novartis). Other 300,050 doses are still pending to be delivered to Peru (26 April).
- Four countries have not confirmed yet their vaccine requests to the RF: Jamaica, St. Kitts & Nevis, St Vincent and the Grenadines and Venezuela.
- Dominica and Dominican Republic have stated their intention of not buying vaccine through the RF. Nevertheless, vaccine has been offered to them through a donation from Spain.



2.2) Direct and Mixed Vaccine Purchase:

Three countries in the Region, Argentina, Brazil and Mexico, have acquired approximately 140 million vaccine doses through direct purchase from laboratories. Brazil has also purchased almost 10 million doses from the Revolving Fund.

2.3) Vaccine Donation Through WHO:

Ten countries in the Region are eligible to receive a donation of 6,974,000 doses of pandemic vaccine through WHO. As of 23 April, countries have received a total of 2,794,000 doses of vaccine (Table 1). There are still 4,180,000 pending doses to be delivered. The arrival date for Paraguay has been delayed until 1 May due to the volcano eruption in Iceland.

Table 1.
Pandemic Influenza (H1N1) Vaccine Donation Status Through WHO

Country	Estimated arrival date	Doses delivered to countries	Doses pending for shipment	Estimated arrival date 2nd shipment	Total doses donated through WHO	Producer laboratory	Adjuvant	Extensión donación OMS	Estimated arrival date
Bolivia	2 April	900,000	-	-	900,000	GSK	Yes	-	-
Cuba	17 March	1,124,000	-	-	1,124,000	GSK	Yes	-	-
El Salvador	21 March	135,000	540,000	30 April	675,000	GSK	Yes	1,600,000	28 April
Guatemala	28 March	260,000	1,040,000	Pending	1,300,000	Sanofi Pasteur	No	-	
Guyana	29 March	75,000	-	-	75,000	Sanofi Pasteur	No	100,000	Pending
Haití	-	-	1,000,000	-	1,000,000	Sanofi Pasteur	No	-	-
Honduras	18 March	140,000	560,000	Pending	700,000	Novartis	Yes	950,000	Pending
Nicaragua	3 March	110,000	440,000	Pending	550,000	Novartis	Yes	200,000	Pending
Paraguay	1 May	-	600,000	-	600,000	Sanofi Pasteur	No	-	-
Suriname	15 April	50,000	-	-	50,000	GSK	Yes	50,000	Pending
Total doses		2,794,000	4,180,000		6,974,000			2,900,000	

WHO has also increased the donation offer to 5 of the previously selected countries: El Salvador, Guyana, Honduras, Nicaragua and Suriname, to cover remaining



vaccine gaps totaling 2,900,000 doses. Of these, the delivery of 1,600,000 doses has been confirmed to El Salvador by 28 April.

Haiti's final decision regarding whether to accept the WHO donated vaccine remains pending.

2.3) Vaccine Donation from Spain:

The Spanish Government has offered a donation of 4,113,870 vaccine doses for 7 countries in the Region (Chile, Cuba, Dominica, Nicaragua, Panamá, Paraguay and Dominican Republic) with remaining vaccine gaps. Administrative procedures are in process to ship this vaccine to the selected countries.

3) Events Supposedly Attributable to Vaccination or Immunization (ESAVI)

With regards to ESAVI surveillance, there have been 1,202 reported ESAVI of which 102 are severe events: Argentina (2), Bahamas (2), Brazil (75), Costa Rica (1), Ecuador (1), Mexico (14), Nicaragua (3), Panama (1), Peru (1) and Suriname (2). Forty one of these reported ESAVI have been classifiedⁱ as events related to Pandemic Influenza (H1N1) vaccine, all of which were reported in Brazil. Sixteen of these cases are anaphylaxis (0.5 events per million doses). The expected anaphylaxis rate is between 1-10 cases per million doses. Also, 16 cases of Guillain-Barré Syndrome are under investigation (4 from Mexico and 12 from Brazil). Six programmatic errors have been notified from one country. All of them were produced because only adjuvant was administered during the vaccination; none presented adverse reactions. Six other probable programmatic errors are being investigated in Brazil and Mexico.

4) The technical documents and advances in vaccination made by countries are continuously updated on the PAHO Immunization website:

http://new.paho.org/hq/index.php?option=com_content&task=view&id=2461&Itemid=569&lang=en

This bulletin is updated with the information stated in the country profiles sent weekly the Member States and the monthly phone conference meetings with PAHO country focal points and national authorities in immunizations, epidemiologic surveillance and regulation authorities.

ⁱ Case classification presented is preliminary, since Specialized National Committees are still working on case classification in basis of a complete case review.